K Allewaert

1,25-Dihydroxyvitamin D3 and osteocalcin in maternal and fetal guinea pigs

Maternal and fetal 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and osteocalcin were measured in guinea pigs, to examine their potential use as animal models for fetal bone development and calcium homeostasis. Measurements were performed on days 42, 57 and 63 of gestation. Maternal serum total 1,25(OH)2D3 concentrations were increased only at the end of gestation (day 63). However, because the vitamin D binding protein (DBP) and albumin levels were decreased by 35-50% from day 42 onwards, the unbound 1,25(OH)2D3, calculated as the 1,25(OH)2D3/DBP molar ratio, was increased before day 63. Osteocalcin concentrations during gestation were 50-54% of levels found in nongravid animals. Fetal serum total 1,25(OH)2D3 concentrations were 20% of those in maternal guinea pigs. Since DBP levels were only 9-15% of maternal levels, the unbound 1,25(OH)2D3 was consistently higher in fetuses, from day 42 onwards. There was a rise in total and unbound 1,25(OH)2D3 between days 57 and 63 of fetal life. Osteocalcin concentrations were higher in fetal than in adult guinea pigs, and reached peak values on day 57 (1023 micrograms/l, i.e. 4.2 times higher than in adult female guinea pigs). Fetuses of guinea pigs that had received a restricted food supply for 14 days (days 49-63) had normal 1,25(OH)2D3 concentrations, but decreased osteocalcin concentrations compared with normal fetuses. The data obtained in fetal guinea pigs are comparable with those found in human fetuses, and suggest that the guinea pig may be a suitable model for studies on fetal bone and mineral development.

Biological evaluation of epoxy analogs of 1α,25-dihydroxyvitamin D3

The biological activity of 16-epoxy side-chain analogs of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) was evaluated in vitro and in vivo. Compared to 1α,25(OH)2D3, all analogs had lower affinities for the pig duodenal vitamin D receptor and also for the human serum vitamin D binding protein. The in vitro effects on cell proliferation or differentiation of human promyeloid leukemia (induction of superoxide production in HL-60 cells), human osteosarcoma MG-63 cells (osteocalcin secretion), or human breast cancer cells (incorporation of thymidine in MCF-7 cells), was markedly inhibited by several epoxy analogs, compared to 1α,25(OH)2D3, but the rank order of their activity widely varied among different cancer cells. The most potent analogs (24S,25S-24-hydroxy-25,26-epoxy-22-ene-1α-OHD3), 25,26-epoxy-23-yne-1α-OHD3 and 25,26-epoxy-23-yne-20-epi-1α-OHD3 or compounds 16, 5, and 7, respectively) were equipotent (16 and 5) or 30-fold (compound 7 on MG-63 cells) to 40-fold (compound 7 on MCF-7 cells) more active than 1α,25-(OH)2D3. These analogs were nevertheless poorly antirachitic (<3%) when tested in vitamin D-deficient chicks (using serum and bone calcium, serum osteocalcin and duodenal calbindin D-28K, as end points). Compound 7 was also 100-fold more active than 1α,25-(OH)2D3 in inhibition of proliferation of human foreskin keratinocytes. Some epoxy analogs of 1α,25-(OH)2D3 thus display interesting dissociations between their receptor affinity and their potency to induce cell differentiation, whereas their effect on cell proliferation/differentiation exceed their calcemic effects more than 100- to 1000-fold.

Synthesis and biological evaluation of 23-oxa-, 23-thia- and 23-oxa-24-oxo-1α,25-dihydroxyvitamin D3

Abstract The synthesis includes the side-chain construction starting from the Inhoffen-Lythgoe diol and coupling with the A ring. Both 23-oxa- and 23-thia-analogues showed a decreased cell differentiating effect but even a more decreased calcemic effect compared with 1α,25-(OH) 2 D 3 .

Synthesis and biological evaluation of some 25,26-epoxy-1α,24-dihydroxyvitamin D3 analogues

Abstract The synthesis of all stereoisomeric 25,26-epoxy-1α,24-dihydroxyvitamin D 3 analogues is described and relies on the Sharpless kinetic resolution of secondary alcohols. It further includes the Julia procedure for side chain construction and the Lythgoe A-ring coupling procedure. Biological evaluation includes the study of calcemic effect, receptor binding and cell differentiation. The synthesis and biological activities of vitamin D 3 analogues containing 25,26-epoxy function (X = OH or H) are presented.

Antagonistic activity of 24-oxa-analogs of vitamin D

24-Oxa-vitamin D3 (24-oxa-D3) and 24-oxa-1 alpha-hydroxyvitamin D3 were designed as possible inhibitors of the vitamin D metabolic activation pathway. Their affinity for the vitamin D receptor (from pig intestine) and human vitamin binding protein were reduced, and their potency to induce cell differentiation of human leukemia cells (HL 60) or osteosarcoma cells (MG 63) was markedly reduced (19% and 3%, respectively), in comparison with calcitriol. A single or chronic injection of 24-oxa-D3 had no biological activity, whereas chronic administration of 24-oxa-1 alpha-hydroxy-D3 showed weak agonist activity in rachitic chicks. When the 24-oxa-D3 was given prior to a single injection of vitamin D3, lower values of serum calcium (64% of the value obtained in vitamin D-treated animals), osteocalcin (52%), 25-(OH)D3 (45%) and duodenal calbindin-D 28K (9.4%) were found. When given chronically in a 100-fold more excess no clear antagonistic effects were observed. 24-Oxa-D3 is thus a new metabolic weak antagonist of vitamin D3, but adding a hydroxyl group at C-1 creates a weak agonist.